PMID- 29527789
OWN - NLM
STAT- MEDLINE
DCOM- 20190124
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 7
DP  - 2018 Jul
TI  - Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty 
      liver disease in patients with type 2 diabetes mellitus.
PG  - 1702-1709
LID - 10.1111/dom.13285 [doi]
AB  - AIMS: To assess the utility of existing metabolomics scores to classify liver 
      disease in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: 
      A total of 220 patients with T2DM were recruited. Patients underwent routine 
      laboratory tests, liver proton magnetic resonance spectroscopy ((1) H-MRS), a 
      75-g oral glucose tolerance test, and liver biopsy if (1) H-MRS findings 
      indicated non-alcoholic fatty liver disease. A serum sample was blindly provided 
      to OWL Metabolomics on which to run the OWLiver Care and OWLiver tests. RESULTS: 
      When compared with liver biopsy, the OWLiver Care and OWLiver tests had a 
      suboptimal performance in patients with T2DM (areas under the receiver-operating 
      characteristic [AUROC] curve both <0.70). Given the discordance of these results 
      in this heterogeneous, multiethnic cohort compared with those of a previous 
      report in predominantly white patients without diabetes, we examined the 
      influence of age, ethnicity and other variables on test performance. A specific 
      subset of patients was selected to mirror the characteristics of the population 
      used for the development of this model (ie, white patients without T2DM). Among 
      white patients with good glycaemic control (glycated haemoglobin <53mmol/mol [or 
      <7%]) and without cirrhosis, the AUROC curve was significantly improved (0.79 [CI 
      95%: 0.68-0.90]). Among white patients with lower insulin resistance (homeostatic 
      model assessment of insulin resistance <3) and without cirrhosis, the AUROC was 
      even higher: 0.87 (CI 95%: 0.76-0.97). CONCLUSIONS: There is a great need to 
      develop non-invasive approaches to diagnose non-alcoholic steatohepatitis in 
      patients with T2DM; models originally developed for patients without diabetes 
      cannot be directly applied to patients with T2DM.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Bril, Fernando
AU  - Bril F
AD  - Division of Endocrinology, Diabetes and Metabolism, University of Florida, 
      Gainesville, Florida.
AD  - Division of Endocrinology, Diabetes, and Metabolism, Malcom Randall Veterans 
      Administration Medical Center, Gainesville, Florida.
FAU - Millan, Laura
AU  - Millan L
AD  - OWL Metabolomics, Derio, Spain.
FAU - Kalavalapalli, Srilaxmi
AU  - Kalavalapalli S
AD  - Division of Endocrinology, Diabetes and Metabolism, University of Florida, 
      Gainesville, Florida.
FAU - McPhaul, Michael J
AU  - McPhaul MJ
AD  - Quest Diagnostics Nichols Institute, San Juan Capristano, California.
FAU - Caulfield, Michael P
AU  - Caulfield MP
AD  - Quest Diagnostics Nichols Institute, San Juan Capristano, California.
FAU - Martinez-Arranz, Ibon
AU  - Martinez-Arranz I
AD  - OWL Metabolomics, Derio, Spain.
FAU - Alonso, Cristina
AU  - Alonso C
AD  - OWL Metabolomics, Derio, Spain.
FAU - Ortiz Betes, Pablo
AU  - Ortiz Betes P
AD  - OWL Metabolomics, Derio, Spain.
FAU - Mato, Jose M
AU  - Mato JM
AD  - CIC bioGUNE, CIBERehd, Derio, Spain.
FAU - Cusi, Kenneth
AU  - Cusi K
AUID- ORCID: 0000-0002-8629-418X
AD  - Division of Endocrinology, Diabetes and Metabolism, University of Florida, 
      Gainesville, Florida.
AD  - Division of Endocrinology, Diabetes, and Metabolism, Malcom Randall Veterans 
      Administration Medical Center, Gainesville, Florida.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180414
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Aged
MH  - Area Under Curve
MH  - Biopsy
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/*metabolism
MH  - Female
MH  - Glucose Tolerance Test
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Insulin Resistance
MH  - Liver/*diagnostic imaging/pathology
MH  - Male
MH  - Metabolomics
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/complications/*diagnosis/metabolism/pathology
MH  - Proton Magnetic Resonance Spectroscopy
MH  - ROC Curve
MH  - Triglycerides/metabolism
OTO - NOTNLM
OT  - NAFLD
OT  - diabetes
OT  - fatty liver
OT  - hepatic steatosis
OT  - obesity
OT  - steatohepatitis
EDAT- 2018/03/13 06:00
MHDA- 2019/01/25 06:00
CRDT- 2018/03/13 06:00
PHST- 2018/01/10 00:00 [received]
PHST- 2018/03/06 00:00 [revised]
PHST- 2018/03/07 00:00 [accepted]
PHST- 2018/03/13 06:00 [pubmed]
PHST- 2019/01/25 06:00 [medline]
PHST- 2018/03/13 06:00 [entrez]
AID - 10.1111/dom.13285 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Jul;20(7):1702-1709. doi: 10.1111/dom.13285. Epub 2018 
      Apr 14.